Table 1 Performance of drug sensitivity prediction using 500 features selected by ProGENI compared to 500 features selected using baseline schemes, for the LCL dataset
From: Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance
Treatment | ProGENI-SVR > PCC-SVR? (FDR, PIF) | ProGENI-SVR > EN-SVR? (FDR, PIF) | Average SPCI (ProGENI-SVR) | Average SPCI (PCC-SVR) | Average SPCI (EN-SVR) |
|---|---|---|---|---|---|
Doxorubicin | Yes (3.94E-11, 71.2%) | Yes (2.79E-38, 93.2%) | 0.660 | 0.641 | 0.498 |
MPA | Yes (4.49E-24, 81.2%) | Yes (2.63E-12, 71.6%) | 0.732 | 0.714 | 0.701 |
TCN | Yes (1.30E-19, 78.8%) | Yes (2.54E-5, 60.4%) | 0.581 | 0.522 | 0.539 |
Everolimus | Yes (1.99E-8, 66%) | Yes (2.63E-12, 69.6%) | 0.595 | 0.570 | 0.554 |
Docetaxel | Yes (1.04E-11, 68.4%) | Yes (2.84E-7, 66%) | 0.608 | 0.585 | 0.579 |
Oxaliplatin | No (1.83E-8, 32.4%) | Yes (5.44E-12, 68%) | 0.676 | 0.694 | 0.633 |
Epirubicin | Yes (2.99E-8, 65.6%) | Yes (1.61E-12, 66.8%) | 0.646 | 0.628 | 0.571 |
NAPQI | Yes (1.11E-7, 66.8%) | Yes (1.47E-2, 56.4%) | 0.597 | 0.575 | 0.583 |
Radiation | Yes (4.30E-8, 66%) | Yes (2.38E-4, 58.8%) | 0.583 | 0.560 | 0.561 |
Carboplatin | Yes (2.66E-7, 64%) | Yes (6.67E-9, 65.2%) | 0.615 | 0.596 | 0.578 |
MTX | No (5.52E-3, 42.4%) | Yes (2.15E-7, 64%) | 0.583 | 0.588 | 0.548 |
Cladribine | Yes (5.68E-7, 63.6%) | Yes (2.58E-5, 62.4%) | 0.622 | 0.602 | 0.597 |
Arac | Yes (5.51E-3, 60.45) | Yes (9.13E-8, 63.2%) | 0.658 | 0.650 | 0.629 |
Paclitaxel | Yes (8.94E-7, 62.8%) | Yes (6.83E-5, 61.2%) | 0.559 | 0.542 | 0.538 |
Arsenic | Yes (4.47E-6, 62.4%) | Yes (1.47E-2, 57.2%) | 0.530 | 0.513 | 0.519 |
6MP | No (1.59E-4, 39.2%) | Yes (2.58E-5, 62.4%) | 0.627 | 0.638 | 0.597 |
Rapamycin | Yes (3.56E-7, 61.2%) | Yes (8.23E-4, 57.6%) | 0.620 | 0.606 | 0.602 |
6TG | No (1.62E-19, 24.8%) | Yes (5.33E-4, 60.8%) | 0.717 | 0.746 | 0.694 |
Metformin | Similar (0.514, 48.4%) | Yes (1.87E-3, 60.4%) | 0.583 | 0.584 | 0.564 |
Fludarabine | Similar (0.655, 46.4%) | Yes (7.54E-5, 59.2%) | 0.539 | 0.540 | 0.512 |
TMZ | Similar (2.99E-2, 54%) | No (4.23E-3, 41.6%) | 0.482 | 0.471 | 0.496 |
Hypoxia | Similar (0.406, 45.6%) | No (4.41E-2, 42.8%) | 0.588 | 0.590 | 0.600 |
CDDP | No (2.01E-3, 44%) | No (5.30E-4, 39.2%) | 0.602 | 0.607 | 0.621 |
Gemcitabine | No (1.10E-4, 37.2%) | excluded | 0.739 | 0.745 | excluded |